bioRxiv Science⌕ Search

Biology subjects

Martemyanov, K. A.

Publications and source records attributed to Martemyanov, K. A..

2 recordsLinked to original sources

TRACR: an anterograde transneuronal tracing system for genetic access across synapses and longitudinal circuit analysis

Following neural signals as they converge onto and diverge from individual neurons is central to understanding circuit function and disease-related dysfunction. Existing anterograde transneuronal tracers are limited by cytotoxicity and incomplete genetic control over connected partners. To address these limitations, we adapted synthetic Notch designs to create TRanssynaptic Anterograde Circuit Readout (TRACR). Binding of the engineered ligand-receptor across synapses induces TRE-driven reporter transcription, enabling characterization of postsynaptic neurons. TRACR provides segregated genetic access to pre- and postsynaptic populations, and can be combined with markers, sensors, or effectors to expand circuit analysis. By applying TRACR at multiple synapses in the mouse visual system, we show that TRACR labels postsynaptic partners of sensory neurons, long-range projections and local inhibitory interneurons. TRACR signaling is reversible and fails to activate when synapses are absent or disrupted. Together, TRACR is an accessible, AAV-deliverable transneuronal reporting tool for longitudinal analysis of circuit assembly, degeneration, and repair. HIGHLIGHTSO_LITRACR adapts the synNotch system to signal across synapses for tracing postsynaptic targets. C_LIO_LITRACR identifies local and long-range postsynaptic targets in the mouse visual system. C_LIO_LITRACR activation requires intact synaptic connectivity rather than proximity. C_LIO_LITRACR signals are reversible, diminishing upon synapse loss and activating following assembly. C_LI

neuroscience↗

Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma

The vasodilator hydralazine (HYZ) has been used clinically for [~] 70 years and remains on the World Health Organizations List of Essential Medicines as a therapy for preeclampsia. Despite its longstanding use and the concomitant progress toward a general understanding of vasodilation, the target and mechanism of HYZ have remained unknown. We show that HYZ selectively targets 2-aminoethanethiol dioxygenase (ADO) by chelating its metal cofactor and alkylating one of its ligands. This covalent inactivation slows entry of proteins into the Cys/N-degron pathway that ADO initiates. HYZs capacity to stabilize regulators of G-protein signaling (RGS4/5) normally marked for degradation by ADO explains its effect on blood vessel tension and comports with prior associations of insufficient RGS levels with human preeclampsia and analogous symptoms in mice. The established importance of ADO in glioblastoma led us to test HYZ in these cell types. Indeed, a single treatment induced senescence, suggesting a potential new HYZ-based therapy for this deadly brain cancer.

biochemistry↗